Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Investor Presentation (March 2024)
32 slides from Sernova Biotherapeutics's investor presentation, March 2024

Slide 1: A future where chronic conditions are no longer insurmountable obstacles
A future where chronic conditions are no longer insurmountable obstacles March 2024 1

Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation is confidential and for your information only and is not intended to be distributed to or reviewed by anyone other than you. This presentation has been prepared by Sernova and is being supplied to you on a confidential basis for informatio

Slide 3: Sernova is Pioneering 'Functional Cures' for Chronic Diseases
Sernova is Pioneering ‘Functional Cures’ for Chronic Diseases Blazing the trail in regenerative medicine Valuable & Expanding Cell Pouch System Therapeutic Cell Platform Portfolio Proprietary technology - Creating true ‘functional cure’ Clinical stage company delivery vehicle for chronic disea

Slide 4: T1D Cohort 1 Patient Testimonial Speaks Volumes
T1D Cohort 1 Patient Testimonial Speaks Volumes Insulin Independent for ~4 Years After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is, to be f

Slide 5: Executive Summary: Advancing Cell Therapeutics for Functional Cures
Executive Summary: Advancing Cell Therapeutics for Functional Cures Pipeline of cell therapies combined with the Cell Pouch delivery vehicle for chronic diseases . The Cell Pouch System – Forms an organ-like environment for administration of cell-based therapies – Ensures complete containment of the

Slide 6: New Developments at Sernova
New Developments at Sernova • 1Q2024: Long term islet survival in Cell Pouch (from P1/2 T1D clinical setting) – histological evidence of abundant, vascularized islets expressing insulin throughout the Cell Pouch chambers – Patient from cohort 2; > 1 year from transplant; patient has sustained elevat

Slide 7: Today to 2026: Potential Milestones & Value Inflection Points
Today to 2026: Potential Milestones & Value Inflection Points Development for T1D, Thyroid Disease & Hem A Continues Across 2024-2026 Data Readouts iPSC preclinical across 2024: (IND enabling) Cohort 2 HDI T1D & pre-clinical thyroid T1D Phase 1/2 T1D Phase 1/2 iPSC asset Thyroid Phase iPSC IND filin

Slide 8: Pipeline Today – Multiple Indications
Pipeline Today – Multiple Indications Impacting patients around the world Therapeutic Indication Cell Source Discovery Pre-Clinical Phase 1/2 Phase 3 BLA Human donor islet cells serves as proof of concept for iPSC study Insulin - dependent Diabetes iPSC islets Hemophilia A Corrected patient cells Au

Slide 9: Implementing a Portfolio Strategy
Implementing a Portfolio Strategy Multiple opportunities to expand our portfolio & to extend our reach to more patients Thyroid Diseases Others Rare Diseases Patient Impact & Internal Commercial development & Assessment; de-risking of Portfolio program Retinal Sernova’s Proprietary Management Diabet

Slide 10: Cell Pouch + Therapeutic Provides Organ-Like Environment
Cell Pouch + Therapeutic Provides Organ-Like Environment Creates vascularized tissue chambers to allow optimal engraftment of therapeutic cells • Cell Pouch is placed deep • After 3 weeks, therapeutic cells • Therapeutic cells are responsive under the skin in a short can be transplanted into the to

Slide 11: Type 1 Diabetes
Type 1 Diabetes Market, Current SOC & Sernova’s Phase 1|2 T1D Study 11

Slide 12: Product Innovation Functional Cure for T1D
Product Innovation Functional Cure for T1D Evolution of program built to expand the treatable patient population Cell Pouch + iPSC 2 Phase 1/2 Planning Underway Cell Pouch + Donor Islets 1 Phase 1/2 Ongoing Cell Pouch iPSC-derived Cell Pouch Islet-Like Donor Clusters (ILCs) Islets “Off the Shelf”

Slide 13: Large Addressable Market for a Functional Cure in T1D
Large Addressable Market for a Functional Cure in T1D Potential to eliminate daily insulin injections and provide tighter blood sugar control United States T1D Population1 Adults with of the 1.6M US adults with T1D 1.6M 400K hypoglycemia unawareness2 25% experience “hypoglycemia unawareness” charact

Slide 14: Advantages of Pancreatic Islet Cell Therapy vs. Insulin Injection
Advantages of Pancreatic Islet Cell Therapy vs. Insulin Injection Pancreatic Islets • Clusters of specialized cells responsible for global regulation of Islets blood glucose • In T1D a patient’s islets become dysfunctional requiring daily insulin injections Pancreas Insulin Injections Alpha Cells On

Slide 15: Phase 1/2 T1D Multi-Cohort Trial Design
Phase 1/2 T1D Multi-Cohort Trial Design Primary Secondary Endpoints Placement of Cell Pouches has been carefully designed & controlled Safety and Survival of islets in Cell Pouch tolerability Reduction in hypoglycemic events Insulin independence was not an endpoint – Proportion of subjects with HbA1

Slide 16: Insulin Independence Achieved in 5 of 6 Patients, Cohort 1
Insulin Independence Achieved in 5 of 6 Patients, Cohort 1 Clinical POC that Cell Pouch supports the engraftment & therapeutic function of transplanted cells. Max Capacity Range: Cumulative Islet Transplants in Cohort 1 10-Channel Cell Pouch 18,000 (Cohort 2) – provides additional space for 16,000 C

Slide 17: Glucose Control in the Non-diabetic Range for All Subjects
Glucose Control in the Non-diabetic Range for All Subjects T1D Phase 1/2 human donor islet study - Cohort 1 Blood Glucose Control – HbA1c 10 9 8 HbA1c (%) 7 6 * 5 4 1011-011(E) 1011-010(D) 1011-009(C) 1011-008(F) 1011-003(A) 1011-007(B) Baseline - Optimal Insulin Therapy Post-Transplant - No Insulin

Slide 18: 5 of 6 Patients Achieved 100% Insulin Independence
5 of 6 Patients Achieved 100% Insulin Independence Phase 1/2 interim update demonstrates safety & tolerability; 1st cohort provided dosing & cell density insight Surgical implantation of the Cell Pouch was found to be well tolerated with a favorable safety profile 5 of 6 patients in first Cohort ach

Slide 19: 2nd Cohort – Favorable First Clinical Update
2nd Cohort – Favorable First Clinical Update Higher capacity allows for higher dosing with optimal islet concentration • Patient enrollment with implantation commenced November 2022 • 6 patients enrolled and implanted with higher capacity 10 channel Cell Pouches – 5 patients have received first isle

Slide 20: Sernova | Evotec Partnership
Sernova | Evotec Partnership iPSC-Derived Islet-Like Clusters (ILCs) 20

Slide 21: iPSC-Islet Like Clusters (ILCs): Long-Term Antidiabetic Efficacy
iPSC- Islet Like Clusters (ILCs): Long-Term Antidiabetic Efficacy Robust, durable normalization of glucose control in diabetic mice Circulating Preclinical Efficient normalization of random fed glucose C-peptide by kidney capsule-implanted ILCs • ILCs demonstrated sustained normalization of blood su

Slide 22: Dose- and Cell Pouch-Dependent Blood Glucose Normalization & C-peptide Levels
Dose- and Cell Pouch-Dependent Blood Glucose Normalization & C-peptide Levels Evotec iPSC ILCs + Sernova Cell Pouch Study #2 – Random Glucose TC + ILC Dose D Study #2 – hC-Peptide • Better glucose responsiveness and CP + ILC Dose D control with Cell Pouch (CP) CP + ILC Dose E compared to control dev

Slide 23: Strong Anti-Diabetic Activity of ILCs in the Cell Pouch
Strong Anti-Diabetic Activity of ILCs in the Cell Pouch Selected clinical dose equivalent provides rapid normalization of glucose control with human islet-like potency Preclinical Robust circulating hC- + ILC Dose D peptide levels comparable to human islets Efficient normalization of random fed gluc

Slide 24: High β-Cell Fraction & Abundant Vascularization of ILCs in Cell Pouch
High β-Cell Fraction & Abundant Vascularization of ILCs Implanted to Cell Pouch in Diabetic Mouse Model INS Histological Assessment at 24 Weeks GCG SST • Abundant endocrine cells with high beta cell DAPI fraction detectable INS • Alpha and delta cells are observed at lower CD31 DAPI frequencies INS

Slide 25: Additional Pipeline
Sernova Additional Pipeline

Slide 26: Cell Pouch System for Thyroid Diseases | Hypothyroidism
Cell Pouch System for Thyroid Diseases | Hypothyroidism One-and-Done treatment provides attractive alternative to life-long medications Therapeutic Benefits & Estimated Market 150,000 1 thyroidectomies performed annually in the US alone Estimated $3.6B 2 market opportunity Market Size First generati

Slide 27: Thyroid Program: In Vivo Efficacy, Proof of Concept in Rat Study
Thyroid Program: In Vivo Efficacy, Proof of Concept in Rat Study Thyroid auto-transplantation into Cell Pouch – Measured Blood Hormone Levels Thyroidectomy (Control) Thyroidectomy + Transplantation of thyroid tissue in Cell Pouch Key Findings • Thyroid removal --> T3/fT4 decreased and TSH increased

Slide 28: Cell Pouch System for Hemophilia A
Cell Pouch System for Hemophilia A Improved Safety Compared to Gene Therapy Approaches Therapeutic Benefits & Estimated Market 60,000 1 patients across North America and EU Estimated Market Size $18B in 2021 reaching $27B by 20312 orphan indication at approx. US$300k annual treatment cost2 Benefits

Slide 29: Hemophilia Program: In Vivo Efficacy of FVIII-BOECs Within Cell Pouch
Hemophilia Program: In Vivo Efficacy of FVIII-BOECs Within Cell Pouch FVIII-corrected BOECs transplanted into the Cell Pouch in NSG-Hemophilic mice FVIII activity in the blood restored hemostasis in hemophilic mice 29 Olgasi et al. Efficient and safe correction of hemophilia A by lentiviral vector-t

Slide 30: Corporate Information
Sernova Corporate Information

Slide 31: Capital Structure | Select Information
Capital Structure | Select Information EXCHANGE: 52-week Range $0.51 – $1.21 TSX: SVA Shares Outstanding 303.3M OTCQB: SEOVF FSE / XETRA: PSH Market Capitalization $210M Average Daily Volume 271K FISCAL Y/E: 10/31 Cash & Equivalents (Q4/ 2023) $21.0M Analyst Coverage Note: market data via TSX Infoli

Slide 32: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH
TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH Head Office Investor Relations Business Development 700 Collip Circle, Ste 114 Christopher Barnes Modestus Obochi, Ph.D., MBA London, ON, Canada N6G 4X8 VP, Investor Relations Chief Business Officer Tel: 1.877.299.4603 1.519.902.7923 1.847.989.1674 Tel: 1.519.8
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023
Sernova — Investor Presentation (May 2023)21 slides · May 2023